MedTrace Logo

MRD Monitoring in Lung Cancer After Resection

NCT04976296 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-03-17

No results posted yet for this study

Summary

The conception of molecular residual disease (MRD) extending from hematologic tumor to solid tumors. Evidences supporting MRD evaluation for lung cancer by liquid biopsy has gradually accumulated, especially circulating tumor DNA (ctDNA). In this observational study, the investigators prospectively enroll stage I-IIIA non-small cell lung cancer (NSCLC) patients who underwent complete resection. Preoperative blood sample, tumor tissue and dynamic postoperative blood samples are collected continuously for MRD detection. This study aim to explore the prognostic value of MRD for stage I-IIIA NSCLC patients after complete resection.

Conditions

Interventions

DIAGNOSTIC_TEST

MRD detection

The Geneplus OncoMRD lung assay is used to detect the MRD status.

Sponsors & Collaborators

  • Guangdong Provincial People's Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2027-12-30
Completion
2027-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04976296 on ClinicalTrials.gov